ATG16L1 and inflammatory bowel disease: Several studies have reported the involvement of single-nucleotide polymorphisms (SNPs) in the response to anti-TNF therapy in IBD patients (rs1800629, rs1799724, rs767455, rs1061624, and rs976881 with an inhibitory effect, while rs4149570, rs361525, and rs3397 determine a superior result), the majority being located in the TNF 1 (TNFR1) and TNF 2 (TNFR2) receptor genes and in those that regulate innate immunity (TLR4, IL6, IL1, IL17, TLR2, TLR9), autophagy, and apoptosis (Fas-L, CASP9, and ATG16L1) [82,83,84].